[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,259
Citations 0
News From the Food and Drug Administration
February 20, 2018

Crackdown on Stem Cell Product

JAMA. 2018;319(7):649. doi:10.1001/jama.2018.0486

A New Jersey–based company that processes and stores stem cell products derived from human adipose tissue has run aground of FDA regulations.

In a warning letter sent last month, the agency notified the American CryoStem Corporation of Eatontown, New Jersey, that its product, Atcell, doesn’t meet criteria that exempt some human cellular and tissue-based products from the FDA approval process. To bypass approval, structural tissues like human fat must meet “minimal manipulation” criteria: they cannot be processed in a way that changes their original form beyond what could safely be used in reconstruction, repair, or replacement procedures.